Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Doxorubicin 26pembrolizumab 24Radiotherapy 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Specimen Handling 14Nivolumab 14Gemcitabine 13Ifosfamide 12Surgical Procedures, Operative 11Biopsy 11Radiation 10X-Rays 8Temozolomide 8Ipilimumab 8pazopanib 7fludarabine 7cabozantinib 7Irinotecan 7tazemetostat 6liposomal doxorubicin 6anlotinib 6Trabectedin 6Surveys and Questionnaires 6Phantoms, Imaging 6Blood Specimen Collection 6olaparib 5eribulin 5atezolizumab 5Vincristine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × crenigacestat × 1 year × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡